Sonoma Pharmaceuticals Inc. (SNOA) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 2.19 High: 2.29

52 Week Range

Low: 1.75 High: 9.37

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $4 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    0.76

  • Industry P/EIndustry P/E information

    36.63

  • Debt to EquityDebt to Equity information

    0.1

  • ROEROE information

    -0.65 %

  • ROCEROCE information

    --

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    --

  • EPSEPS information

    -3.93

10 Years Aggregate

CFO

$-71.02 Mln

EBITDA

$-81.84 Mln

Net Profit

$-49.28 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Sonoma Pharmaceuticals (SNOA)
-17.47 -38.67 -16.23 -26.00 -66.75 -53.14 -44.53
BSE Sensex*
1.72 3.50 4.95 8.90 11.18 21.04 11.14
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 21-Apr-2025  |  *As on 22-Apr-2025  |  #As on 26-Oct-2023
2024
2023
2022
2021
2020
2019
2018
Sonoma Pharmaceuticals (SNOA)
-25.10 -83.93 -75.44 -37.19 66.51 -32.01 -86.78
S&P Small-Cap 600
7.01 13.89 -17.42 25.27 9.57 20.86 -9.70
BSE Sensex
8.10 18.74 4.44 21.99 15.75 14.38 5.87

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
58.65 11,346.08 26.77 8.05
62.90 6,566.51 50.6 23.56
56.80 11,265.03 388.07 0.76
7.57 9,024.30 -- -3.24

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and...  internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado. Address: 5445 Conestoga Court, Boulder, CO, United States, 80301  Read more

  • CEO, President & Director

    Ms. Amy M. Trombly

  • CEO, President & Director

    Ms. Amy M. Trombly

  • Headquarters

    Boulder, CO

  • Website

    https://sonomapharma.com

Edit peer-selector-edit
loading...
loading...

FAQs for Sonoma Pharmaceuticals Inc. (SNOA)

The total asset value of Sonoma Pharmaceuticals Inc (SNOA) stood at $ 17 Mln as on 31-Dec-24

The share price of Sonoma Pharmaceuticals Inc (SNOA) is $2.22 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Sonoma Pharmaceuticals Inc (SNOA) has given a return of -66.75% in the last 3 years.

Sonoma Pharmaceuticals Inc (SNOA) has a market capitalisation of $ 4 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Sonoma Pharmaceuticals Inc (SNOA) is 0.76 times as on 21-Apr-2025, a 85% discount to its peers’ median range of 4.97 times.

Since, TTM earnings of Sonoma Pharmaceuticals Inc (SNOA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sonoma Pharmaceuticals Inc (SNOA) and enter the required number of quantities and click on buy to purchase the shares of Sonoma Pharmaceuticals Inc (SNOA).

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado. Address: 5445 Conestoga Court, Boulder, CO, United States, 80301

The CEO & director of Ms. Amy M. Trombly. is Sonoma Pharmaceuticals Inc (SNOA), and CFO & Sr. VP is Ms. Amy M. Trombly.

There is no promoter pledging in Sonoma Pharmaceuticals Inc (SNOA).

Sonoma Pharmaceuticals Inc. (SNOA) Ratios
Return on equity(%)
-76.14
Operating margin(%)
-24.56
Net Margin(%)
-26.82
Dividend yield(%)
--

No, TTM profit after tax of Sonoma Pharmaceuticals Inc (SNOA) was $0 Mln.